Oncoinvent ASA — Proxy Solicitation & Information Statement 2026

Apr 28, 2026

Oncoinvent ASA: Notice of Annual General Meeting

Oncoinvent ASA: Notice of Annual General Meeting

Oslo, Norway, 28 April 2026 - Oncoinvent ASA (ONCIN), will be holding its Annual

General Meeting virtual on 20 May 2026 at 10:00 hours (CEST).

The notice and agenda of the annual general meeting is attached hereto,

including further information on advance voting, power of attorney and physical

participation. The notice will be sent to all registered shareholders, and the

notice, the compensation report, the nomination committees recommendations and

other documents referred to therein are made available on the Company's website:

https://www.oncoinvent.com/investors/general-meetings/.

Oncoinvent ASA - Notice to AGM

2026.pdf (https://mb.cision.com/Public/15728/4341307/91b5ce77dcea1d84.pdf)

All shareholders are encouraged to exercise their shareholder rights, either

through advance electronically voting through VPS Investor Services, by using

the enclosed proxy form to provide proxy to the Chairman Gillies O'Bryan-Tear

(or the person he appoints), or to attend the general meeting virtually.

Registration, advance vote or proxy for the Annual General Meeting can be

registered through the company's

website (https://www.oncoinvent.com/investors/general-meetings/) or VPS Investor

Service (https://investor.vps.no/garm/auth/login) within 18 May 2026, 23:59

hours (CEST). Virtual participants also need to be logged in to the meeting

before 10:00 hours (CEST) 20 May 2026. All shareholders will receive a reference

number and a pin code required for registration through the company's website.

Reference number and pin code will be received either by VPS Investor Service or

by post depending on if the shareholder is registered as electronical user. We

encourage all shareholders to register as electronical users in VPS.

For further information, please contact:

Oystein Soug, Chief Executive Officer

Email: IR@oncoinvent.com (soug@oncoinvent.com)

This information is subject to the disclosure requirements pursuant to Euronext

Oslo Rule Book II for companies listed on Oslo Børs and Section 5-12 of the

Norwegian Securities Trading Act.

About Oncoinvent

Oncoinvent is developing Radspherin[®], a receptor-independent alpha radiation

therapy that leverages the unique anatomy of the abdominal cavity to destroy

residual micrometastases using a single, highly localized dose of alpha

radiation. The initial clinical focus is treatment of ovarian and colorectal

cancer patients after surgical removal of the primary tumor and visible

metastases in the peritoneum, the thin membrane lining the abdominal cavity and

covering the abdominal organs.

This radiopharmaceutical is designed to prevent or delay recurrence in the

peritoneal cavity, keeping patients disease-free for longer than the current

standard of care and thereby also impacting overall survival. It is broadly

applicable to any cancer that spreads to the peritoneum, e.g. ovarian,

colorectal, and gastric cancers. Radspherin[®] stands out for its simplicity,

excellent safety profile, and seamless integration into existing surgical

workflows. Oncoinvent's product is easy to use, avoids systemic delivery and

significant toxicity. It is also differentiated in being simple to manufacture,

scalable, and supply de-risked.

Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers,

are highly promising, showing an excellent safety profile and meaningful signals

of efficacy. Interim data from an ongoing, randomized, controlled phase 2

ovarian cancer trial is expected in 2026. With cost-effective manufacturing,

blockbuster potential, active pharma partnership momentum, plus strong

endorsements from leading experts, Oncoinvent is built for scale and commercial

success, and is set to become the new standard for post-surgical cancer care.

The Company was founded by the originators of Algeta and Xofigo (acquired by

Bayer).